drugset
drugset / Trial / NCT01149902

Study of Chemo-Immunotherapy in Head and Neck Cancer Patients

NCT01149902 ↗

Phase 1 Unknown 10 enrolled University of Yamanashi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients with relapsed and refractory head and neck squamous cell carcinoma.

Timeline

Start
2010-07
Primary completion
2012-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg —
Subject Dendritic cells Cell therapy — —
Subject Docetaxel Small molecule 30 mg/m2 —
Subject OK-432 Unknown 5 unknown —

Indications

head and neck cancer